公开(公告)号：WO2006088833A3

公开(公告)日：2006-11-23

申请号：PCT/US2006005111

申请日：2006-02-14

Applicant: WYETH CORP ,  CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

Inventor： CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

IPC: C07K16/24 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61P29/00 ,  A61P37/00 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/113 ,  G01N33/68

CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

Abstract translation: 本发明提供了与IL-17F信号传导途径相关的分离和纯化的多核苷酸和多肽。 本发明还提供针对IL-17F同二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异二聚体）的方法。 本发明还涉及用于诊断，预测，监测IL-17F信号传导即IL-17F相关病症（包括但不限于炎症）的进展和治疗和/或预防与IL-17F信号传导相关的病症的新方法 （例如，关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，变态反应），移植排斥（包括实体器官移植排斥 ）和炎性肠病或病症（IBD，例如溃疡性结肠炎，克罗恩氏病）。 本发明还涉及新的治疗剂和治疗靶，以及筛选和评估测试化合物用于干预（治疗）和预防与IL-17F信号传导相关的病症的方法。

公开(公告)号：WO2008121865A1

公开(公告)日：2008-10-09

申请号：PCT/US2008/058735

申请日：2008-03-28

Applicant: WYETH ,  WRIGHT, Jill, F. ,  LIANG, Spencer, C. ,  BENNETT, Frances, K. ,  COLLINS, Mary ,  CARRENO, Beatriz, M.

Inventor： WRIGHT, Jill, F. ,  LIANG, Spencer, C. ,  BENNETT, Frances, K. ,  COLLINS, Mary ,  CARRENO, Beatriz, M.

IPC: G01N33/68

CPC classification number: G01N33/6869 ,  G01N2333/54 ,  G01N2500/02

Abstract: The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A- associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g., using the mouse model of airway inflammation), as well as methods of identifying whether the IL-17F/IL-17A modulator is a specific IL-17F/IL-17A modulator. The invention is also directed to novel methods for diagnosing, prognosing, monitoring, preventing, and/or treating IL-17F/IL-17A-associated disorders, including, but not limited to, inflammatory disorders (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., airway inflammation, chronic obstructive pulmonary disease, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets identified by methods of screening of the invention, and uses of such identified therapeutics in methods of treatment and prevention of IL- 17F/IL- 17A-associated disorders.

Abstract translation: 本发明提供了一种新型小鼠IL-17F / IL-17A，并且还提供了这种小鼠IL-17F / IL-17A在IL-17F / IL-17A异二聚体表征中的用途。 本发明还涉及IL-17F / IL-17A信号通路的多核苷酸和多肽，以及IL-17F / IL-17A信号通路在治疗IL-17F / IL-17A-相关疾病的方法中的靶向。 因此，本发明提供了使用分离的IL-17F / IL-17A异二聚体的方法，例如在气道炎症的小鼠模型中，以及特异性或选择性IL-17F / IL-17A调节剂（例如，信号传导激动剂或信号传导拮抗剂 特异性或选择性拮抗性抗体，特异性或选择性拮抗性小分子等））。 本发明还提供筛选能够调节IL-17F / IL-17A生物活性的化合物的方法，例如IL-17F / IL-17A信号传导拮抗剂（例如，使用气道炎症的小鼠模型），以及 识别IL-17F / IL-17A调节剂是否是特异性IL-17F / IL-17A调节剂。 本发明还涉及用于诊断，预后，监测，预防和/或治疗IL-17F / IL-17A相关疾病的新方法，包括但不限于炎症性疾病（例如关节炎（包括类风湿性关节炎） ，牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如气道炎症，慢性阻塞性肺病，囊性纤维化，哮喘，过敏），移植排斥（包括实体器官移植排斥）和炎性肠病或疾病 例如溃疡性结肠炎，克罗恩病）。 本发明还涉及通过筛选本发明的方法鉴定的新型治疗学和治疗靶标，以及这些鉴定的治疗剂在治疗和预防IL-17F / IL-17A相关疾病的方法中的用途。

公开(公告)号：WO0043781A3

公开(公告)日：2001-02-01

申请号：PCT/US0001552

申请日：2000-01-21

Applicant: METAMORPHIX INC ,  TOPOUZIS STAVROS ,  WRIGHT JILL F ,  RATOVITSKI TAMARA ,  LIANG LI FANG ,  BRADY JAMES L JR ,  SINHA DEBASISH ,  YASWEN CORKERY LINDA

Inventor： TOPOUZIS STAVROS ,  WRIGHT JILL F ,  RATOVITSKI TAMARA ,  LIANG LI-FANG ,  BRADY JAMES L JR ,  SINHA DEBASISH ,  YASWEN-CORKERY LINDA

IPC: A01K67/027 ,  A61K38/00 ,  A61K45/00 ,  A61P3/04 ,  A61P3/10 ,  A61P11/00 ,  A61P19/00 ,  A61P25/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/475 ,  C12N9/99 ,  C12N15/09 ,  C12N15/85 ,  C12Q1/37 ,  C12Q1/50 ,  G01N30/88 ,  G01N33/15 ,  G01N33/50 ,  G01N33/68 ,  C07K7/06 ,  C07K7/08 ,  C07K14/51 ,  C12N9/00 ,  C12N15/11

CPC classification number: A01K67/0275 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/02 ,  A01K2267/03 ,  C07K14/475 ,  C07K2319/00 ,  C12N15/8509 ,  C12N2830/008 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/6872

Abstract: Inhibitors of GDF proteins, such as GDF-8 or GDF-11, are disclosed. Also disclosed are methods for identifying and using the inhibitors, for example, to generate transgenic animals and to treat a variety of diseases.

Abstract translation: 公开了GDF蛋白的抑制剂，例如GDF-8或GDF-11。 还公开了用于鉴定和使用抑制剂的方法，例如产生转基因动物并治疗多种疾病。

公开(公告)号：WO2006088833A2

公开(公告)日：2006-08-24

申请号：PCT/US2006/005111

申请日：2006-02-14

Applicant: WYETH ,  CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

Inventor： CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

IPC: C07K16/24 ,  C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/11 ,  G01N33/68 ,  A61K39/39 ,  A61K39/395 ,  A61P37/00 ,  A61P29/00 ,  A61K38/20

CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

Abstract translation: 本发明提供与IL-17F信号通路相关的分离和纯化的多核苷酸和多肽。 本发明还提供了对IL-17F同源二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异源二聚体）的方法。 本发明还涉及用于诊断，预后，监测与IL-17F信号传导相关的疾病的进展和/或预防的新方法，即IL-17F相关疾病，包括但不限于炎性 诸如自身免疫性疾病（例如关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，过敏），移植排斥（包括实体器官移植排斥 ）和炎症性肠病或疾病（IBD，例如溃疡性结肠炎，克罗恩病）。 本发明还涉及新的治疗和治疗靶标，以及筛选和评估用于干预（治疗）的试验化合物和预防与IL-17F信号传导相关的紊乱的方法。